Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activating mTOR Mutations Are Detrimental in Nutrient-Poor Conditions.

Cancer research - 16 Sept 2022

Bielska Agata A, Harrigan Caitlin F, Kyung Yeon Ju, Morris Quaid, Palm Wilhelm, Thompson Craig B

Abstract excerpt

The mTOR is a key regulator of cell growth that integrates growth factor signaling and nutrient availability and is a downstream effector of oncogenic receptor tyrosine kinases (RTK) and PI3K/Akt signaling. Thus, activating mTOR mutations would be expected to enhance growth in many tumor types. However, tumor sequencing data have shown that mTOR mutations are enriched only in renal clear cell carcinoma, a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell
Share to Kidney Neoplasms
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nutrients

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Share to TOR Serine-Threonine Kinases

Share to Tyrosine

Source

Open in PubMed Open full text

Identifiers

PMID: 35857801
DOI: 10.1158/0008-5472.CAN-22-0121
PMCID: PMC10094744

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activating mTOR Mutations Are Detrimental in Nutrient-Poor Conditions.PMID 35857801Read ↗

A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.Semantic proximity Read ↗

Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.Semantic proximity Read ↗

Amino Acid Transporters Are a Vital Focal Point in the Control of mTORC1 Signaling and Cancer.Semantic proximity Read ↗

Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.Semantic proximity Read ↗

Review: Mammalian Target of Rapamycin (mTOR) Pathway Is Critical in Developing Most Renal Cell Tumors.Semantic proximity Read ↗

Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma.Semantic proximity Read ↗

Mutant ras elevates dependence on serum lipids and creates a synthetic lethality for rapamycin.Semantic proximity Read ↗

An expanding role for mTOR in cancer.Semantic proximity Read ↗

Nutrient regulation of mTORC1 at a glanceSemantic proximity Read ↗

Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myelomaSemantic proximity Read ↗

Autoregulation of the mechanistic target of rapamycin (mTOR) complex 2 integrity is controlled by an ATP-dependent mechanism.Semantic proximity Read ↗

Kaposi sarcoma–associated herpesvirus miRNAs suppress CASTOR1-mediated mTORC1 inhibition to promote tumorigenesisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.